苏州星曜坤泽生物制药

Xingyao Kunze is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of innovative therapies for liver diseases, with a primary focus on chronic hepatitis B (CHB). The company leverages its proprietary GalNAc-siRNA delivery platform and antibody engineering capabilities to create a synergistic pipeline aimed at achieving a functional cure for HBV. Its lead programs include XYK2021, a GalNAc-conjugated siRNA designed to silence viral transcripts, and XYK001, a potent neutralizing monoclonal antibody. Backed by prominent venture capital firms including Hillhouse Capital and Lilly Asia Ventures, Xingyao Kunze aims to address significant unmet medical needs in the global hepatology market through precision medicine and advanced delivery technologies.